Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504391 | 0.95 | PDPK1 (0.49) | PTGS2PTGS1CYP2C9PDPK1ALOX5 | |
| SCHEMBL14504394 | 0.93 | PTGS2 (0.41) | PTGS2PTGS1CYP2C9PDPK1ALOX5 | |
| SCHEMBL14504630 | 0.87 | PTGS2 (0.44) | PTGS2PTGS1CYP2C9PDPK1ALOX5 | |
| SCHEMBL14504387 | 0.87 | PTGS2 (0.68) | PTGS2PTGS1CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL14504423 | 0.86 | PTGS2 (0.55) | PTGS2PTGS1CYP2C9PDPK1CYP1A2 | |
| SCHEMBL14504549 | 0.86 | PTGS2 (0.53) | PTGS2PTGS1CYP2C9PDPK1CYP1A2 | |
| SCHEMBL14505123 | 0.85 | PDPK1 (0.51) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5147748 | 0.85 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL14505041 | 0.85 | RPA1 (0.48) | — | |
| SCHEMBL14504411 | 0.85 | PTGS2 (0.53) | PTGS2PTGS1CYP2C9PDPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | PTGS2 1780/4885PTGS1 1105/4885CYP2C9 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.